Prevalence and Determinant of Adverse Drug Reactions Among MDR-TB Patients Attending St. Peter's TB Specialized Hospital, Addis Ababa, Ethiopia.

4 Fikru Letose Shararo^{1*}, Degemu Sahlu Asebe², Hawine Teshome Teshome³, Sahle Asfaw Jabo⁴,

5 Affiliation

- 6 ^{1*}Gambella Peoples' Regional National State Health Bureau, Gambella, Ethiopia.
- ⁷²College of health Science, department of public health, Selale University, Fiche, Ethiopia.
- 8 ³College of health science, Addis Ababa University, Addis Ababa, Ethiopia.
- ⁹ ⁴College of health Science, Kotbe metropolitan University, Addis Ababa, Ethiopia.
- 10 E-mail address: FL:fikruletose6@gmail.com, DS:kergadegemu@gmail.com,
- 11 HT:hawinetes@gmail.com, SA: sahleasfaw1919@gmail.com,
- 12 Corresponding Author: Fikru Letose Shararo; PO Box: 109; Mobile Number; +251921416858;
- 13 Email address: [fikruletose6@gmail.com]
- 14 FL: MPH
- 15 DS: MPH
- 16 HT: MPH
- 17 SA: MPH
- 18 Research type: Research article
 - 1 | Page

20 Abstract

Background: Tuberculosis is one of a major public health problem throughout the world. About 9.6 million people were estimated to have Tuberculosis in 2014. Out of this, 480 000 cases were multidrug-resistant Tuberculosis. Thus, it has to be identified, focused and prioritized for subsequent and targeted interventions. Therefore, the aim this study was to assess the prevalence and factors affecting adverse drug reaction among multidrug-resistant Tuberculosis patients.

Method: Institution based retrospective cross sectional study design was included all patients 26 27 with Multi Drug Resistant who were registered and treated from 9 January 2020 to 30 March 28 2020. Data abstraction form was used to obtain patient information from their cards. Data were 29 collected by trained nurses who have been working at multidrug-resistant Tuberculosis treatment 30 service. Data were entered, cleaned and checked using Epi Data version 4.6 statistical software 31 and analyzed by SPSS version 23. Bivariate and multivariate logistic regression analyses were 32 used to examine the association between independent and dependent variables. The results were presented as Odds Ratio with 95% CI. 33

34 **Result:** A total of 286 patients were included in the study. The prevalence of adverse drug 35 reaction in this study were 169 (59.1%). Factors such as Treatment outcome and comorbidity 36 were significantly associated with adverse drug reaction among multidrug-resistant Tuberculosis 37 patients.

38 Conclusion and Recommendation: There was high prevalence of adverse drug reaction among 39 multidrug-resistant Tuberculosis patients. Comorbidity and treatment outcome were the 40 independent determinants. Patients who are identified with adverse drug events need special 41 attention enhanced clinical management.

42 **Key word**: Adverse drug reaction, MDR-TB, Institution based cross sectional study.

43 Introduction

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis; a rod-shaped
bacillus called "acid-fast" due to its staining characteristics in laboratory. Occasionally the
disease can also be caused by Mycobacterium Ovis and Mycobacterium africanum(1).

TB is considered drug-resistant when the TB causative agent is not killed by one or more of the available anti-TB drugs. Drug-resistant TB can be primary or secondary (acquired). Primary resistance is drug resistance among new cases, while secondary resistance is drug resistance among previously treated cases(1, 2).

Treatment for multidrug-resistant Tuberculosis (MDR-TB) is longer, and requires more expensive and more toxic drugs. For most patients with MDR-TB, the current regimens recommended by WHO lasts 20 months and treatment success rates are much lower(3). In Ethiopia, MDR-TB patients are treated with standardized second line treatment regimen for at least 18-24 months. Drug Resistance Survey (DRS) data from representative patient populations are used to design a standardized treatment regimen(2).

Globally, an estimated 3.3% of new TB cases and 20% of previously treated cases have MDRTB in 2014. From these MDR-TB cases, an estimated 190,000 people died. Despite the number
of TB deaths is unacceptably high, with a timely diagnosis and correct treatment almost all
people with TB can be cured(3).

The prevalence and mortality of Tuberculosis of all forms is estimated to be 546 and 73 per 100,000 populations respectively. In the year 2006/7 Ethiopia registered 129,743 cases of TB. According to latest estimates, Ethiopia stands 7th in the list of High Burden Countries for TB.

According to the MOH hospital statistics data, tuberculosis is the leading cause of morbidity, the
third cause of hospital admission (after deliveries and malaria), and the second cause of death in
Ethiopia, after malaria(1).

Patients with MDR-TB take more tablets and receive more injections for a longer period of time, may experience more adverse effects and require increased support to continue treatment and/or to monitor adverse effects. Detecting and controlling adverse effects in a timely manner promotes adherence and prevents default to treatment(1, 4).

Unmanaged adverse reactions greatly affect the patients' adherence to treatment regimen, which in turn leads to the development of drug resistance(4). This study is intended to determine the current management practice of adverse drug reactions among MDR-TB patients on second-line anti-tuberculosis drug regimen. In addition, health care practitioners' knowledge and patient's understanding of their treatments will be assessed with this study.

76 Material and Methods

77 Study design, setting, and period

Institution based retrospective cross sectional study was conducted at St. Peter's TB Specialized
Hospital from 9 January 2020 to 30 March 2020.

It was inaugurated on February 04, 1963 as "St. Peter's TB Clinic" by Emperor Haile Selassie I. St. Peter's has served as the only specialised TB referral hospital in Ethiopia for four decades. Afterwards, by the government's decision TB treatment centres were opened in every region of the country and that has alleviated the burden which had been laid on St. Peter's. St. Peter's is the first hospital to offer medical services to patients with drug resistant TB. The hospital has a

total of 400 staffs during the study period and 286 patients with MDR-TB who were registered
and treated during 9 January 2020 to 30 March 2020.

87 Study participants and sampling procedures

All MDR-TB patients who were treated with anti-TB drugs at St. Peter's TB Specialized Hospital were the source population. Whereas, all MDR-TB patients attended St. Peter's TB Specialized Hospital and treated by second- line anti-TB drugs and aged 18 and above were study population. All records of patients who have been on treatment from 9 January 2020 to 30 March 2020 at St. Peter's TB Specialized Hospital were reviewed (**Fig 1**) and 286 patients profile cards that fulfill the inclusion criteria were incorporated in the study.

94 Data collection instruments and methods

A data abstraction form was developed so as to meet the objectives of this study. It was used to 95 obtain the required information from the patient's medical chart. The form consisted of questions 96 regarding socio-demographic characteristics, clinical characteristics, treatment regimens, adverse 97 drug reactions and ADR managements. The list of patients needed for the study was obtained 98 from the hospital's database. After getting the list of the patients, their charts were retrieved from 99 the record and documentation office. A data abstraction format was used to record the necessary 100 information from patients' chart. The data were collected by trained nurses who are staff of 101 MDR-TB ward. 102

103 Variables of the Study

The dependent variable was adverse drug reactions. Whereas, the independent variables include
Age, Sex, Marital status, educational status, Occupational status, Co-morbidity, MI, Site of TB,

Anti-TB drugs, Treatment outcome, History of smoking, History of alcohol use and Drug abusehistory.

108 Measurements

109 New: A patient who has received no or less than one month of anti-tuberculosis treatment.

110 **Relapse:** A patient who was previously treated for TB and whose most recent treatment outcome

111 was "cured" or "treatment completed", and who is subsequently diagnosed with recurrent

episode of TB.

113 **Treatment after being lost to follow-up:** A patient after taking treatment for more than one

month who returns to treatment following interruption of treatment for two or more consecutivemonths.

Treatment after failure of New TB regimen: A patient who has received new regimen for TB and in whom treatment has failed. Failure is defined as sputum smear/culture positive at five months or later during treatment.

119 Treatment after failure of Retreatment regimen: A patient who has received retreatment
120 regimen for TB and in whom treatment has failed. Failure is defined as sputum smear/culture
121 positive at five months or later during treatment.

Transfer in: A patient who has been transferred from another TIC to continue MDR-TBtreatment.

124 **Other:** Refers to any DR-TB patient who does not fit into any of the above categories.

Cured: Treatment completed according to national recommendation without evidence of failure
and three or more consecutive cultures taken at least 30 days apart are negative after the
intensive phase.

Treatment completed: Treatment completed according to national recommendation without evidence of failure but no record that three or more consecutive cultures taken at least 30 days apart are negative after the intensive phase.

Treatment failed: Treatment terminated or need for permanent regimen change of at least two anti-TB drugs because of; lack of conversion by the end of the intensive phase, or bacteriological reversion in the continuation phase after conversion to negative after intensive phase, or evidence of additional acquired resistance to fluoroquinolones or second line injectable drugs, or adverse drug reactions.

Lost To Follow Up (LFTU): A patient whose treatment was interrupted for two consecutivemonths or more

Died: A patient who dies for any reason during the course of treatment

ADR: A response to a drug which is noxious and unintended, and which occurs at doses
normally used in human for the prophylaxis, diagnosis, or therapy of disease, or for the
modification of physiological function.

142 Side Effects: An expected, well-known reaction resulting in little or no change in patient143 management.

144 **Data quality control**

Four data collectors (Diploma nurse) were trained on the content of the questionnaire and the objective of the study for 03 days. A pre-test was done at 5% of the sample size, at another district before the actual data collection. A structured interviewer administered questionnaire was used for the data collection. The supervisor and the investigator were checked the data for completeness, missing, and unwanted filling daily. Epi data manager version 4.6.0.4 was used for data entry. SPSS version 23 was used for the analysis.

151 Ethical Consideration

Ethical clearance was obtained from the ethics Institutional Review Board (IRB) of Addis Ababa University. A formal letter from Addis Ababa University was submitted to St. Peter's TB Specialized Hospital and permission was obtained. Written informed consent for participation was not required for this study. To ensure confidentiality, name and other identifiers of the patients were not recorded on the data abstraction formats.

157 Data processing and Analysis

Data was entered, cleaned and checked for the completeness using Epi data version 4.6 statistical 158 159 software. Errors related to inconsistency were verified using cross data exploration techniques. Then managed data was exported to Statistical Package for Social Sciences (SPSS) software 160 version 23. Descriptive analysis was done using frequency and percentages for the variables. 161 162 Logistic regression was used to analyze the associations between different variables. Factors that were associated with ADR at 95% significance level in the bivariate analysis were included in 163 the final multivariate analysis. Statistical significance was declared if the p-value is less than 164 0.05. 165

166 **Results**

167 Socio-Demographic Characteristics

The mean age (\pm SD) of the patients who have participated in this survey was 29.58 years (\pm 11.4) and their age ranged from 18 to 75 years. Regarding the sex of the participants 159 (55.6%) were males. More than half, 181 (63.3%) of the patients were from Addis Ababa, followed by the Oromia region 45 (15.7%). Almost equal numbers of the patients are single 136 (47.6%) and married 138 (48.3%). Most of the patients have attended education within the grade levels 1 up to 8, 93 (32.5%) and 9 up to 12, 86 (30.1%) (**Table 1**).

174 Clinical Characteristics

Most of the patients had pulmonary TB, 270 (94.4%). Additionally, majority of the patients; 244 (85.3%) had a prior history of TB treatment (failure, default and relapse cases). The majority of the patients 270 (94.4%) had no co-morbidities while the rest had co-morbidities such as diabetes and cardiomyopathy. The most frequently used 251 (87.8%) treatment regimen was capreomycin (Cm), levofloxacin (Lfx), pyrazinamide (Z), ethionamide (Eto)/Prothionamide (Pto) and cycloserin (Cs). (**Table2**)

181 Frequency, management and Treatment outcomes of ADR

Out of 286 patients, 169 (59.1%) were found to be experiencing symptoms associated with ADRs. Most of the patients experienced combination of ADRs. The most common ADR was nausea and vomiting (57.4%) followed by dyspepsia and abdominal pain (44%) and arthralgia (43.5%). Other ADRs also included headache (22.5%), insomnia (21.3%), anorexia (18.9%), and others (**Table3**). From 169 patients, proper management of ADR was given for 119(70.4%)

patients (Fig2). One hundred fifty-three (53.5%) patients completed their treatments. While 78
(27.3%) of the patients were cured (Table 3).

189 Treatment regimens used

The highest number 251 (87.8%) of the patients took the standard treatment regimen which is the
combination of Cm, Lfx, Pto/ Eto, Cs, Z during the intensive phase and Lfx, Pto/ Eto, Cs, Z
during the continuation phase (**Table 4**).

193 Multivariate analysis of factors and adverse drug reaction

Variables with P < 0.02 during the bivariate analysis were included in the multivariate logistic 194 regression analysis to see the effect of confounding variables. 195 The multivariate analysis indicated that comorbidity and treatment outcomes showed statistically significant association 196 with adverse drug reaction. But age and smoking did not show significant association with 197 adverse drug reaction. The odds of adverse drug reaction in patients who had comorbid diseases 198 were about 6 times higher than those who had no the diseases (AOR = 5.809, 95%CI (1.106 -199 30.504)). Treatment outcome was significantly associated with adverse drug reaction. Patients 200 who had treatment outcome of cure were more likely to develop adverse drug reaction 201 202 (AOR=10.012, 95% CI, (2.131 - 47.036)) than those who had treatment outcome of failure (Table 5) 203

204 **Discussion**

In this study, 59.1 % of the participants developed symptoms associated with ADRs these is higher compared with Previous studies have documented a prevalence rate of 44% in Nigeria(5),50% in India(6),50.5% in Vietnam (7). Another study in India has also found a

10 | Page

208 prevalence of 33.96%(8). This finding is considerably higher than those given in previous reports 209 and the observed variation could be a result of disparity in the definitions of adverse drug 210 reactions used by the researchers, the study design used, the geographic variation, the specific 211 anti-TB drugs used and the time at which the study was conducted.

The most common ADR experienced by participants were nausea and vomiting (57.4%) followed by dyspepsia and abdominal pain (44%) and arthralgia (43.5%). Other reported ADRs include headache (22.5%), insomnia (21.3%) and anorexia (18.9%). The result is inconsistent with those reported by (4-8). This difference may be attributed to the difference in the pharmacokinetic parameter of the patients, use of different anti –TB regimens and their doses among countries.

The drugs most likely associated with nausea and/or vomiting were capreomycin, levofloxacin, 218 219 ethionamide/protionamide and pyrazinamide. Most of the aforementioned drugs also cause 220 dyspepsia. This finding is also comparable the other findings reported by Haregewoin and Petros (4, 9, 10). Majority of the patients experienced gastrointestinal symptoms during early weeks of 221 treatment. These symptoms may prevent the delivery of adequate therapy and lead patients for 222 223 further problem. Gastrointestinal side effects which were commonest can be largely prevented by proper timing and spacing of drugs with food and if necessary, giving antiemetic, antacids and 224 225 proton pump inhibitors (PPIs) or H2 receptor blockers.

Arthralgia was found to be one of the common ADR encountered by patients in this study. It was likely caused by pyrazinamide and levofloxacin(9). The present finding is inconsistent with study findings from India(8). The discrepancy may be due to variation in inclusion of the causative drugs in the national MDR-TB treatment protocol between the countries.

This study identified determinants of adverse drug reaction among the patients attending St. Peter hospital in Addis Ababa Ethiopia. Comorbidity and treatment outcome were the independent determinants of adverse drug reaction of the patients. But it found that any of the socio demographic characteristics were not statistically significant with the development of adverse drug reaction.

Treatment outcome was significantly associated with adverse drug reaction. The odds of adverse drug reaction in patients whose treatment outcome of cure were about 10 times higher than (AOR=10.012, 95% CI, (2.131 - 47.036)) those whose treatment outcome of failure. The study finding was also in line with studies conducted in India and Russia (6, 10-12). The possible reason could be those patients who were cure might be closely followed by tuberculosis treatment care providers and as a result they got better reporting of ADRs and favorable treatment outcome.

The study revealed that MDR-TB patients who had comorbid diseases were about 6 times more likely (AOR = 5.809, 95%CI (1.106 - 30.504)) to develop adverse drug reaction than those who had not the disease. This finding is consistent with previous reports(13-15). In the presence of comorbidities, the patients take several drugs, whether prescription or over the-counter, contributes to the risk of having an ADR. The number and severity of ADRs increases disproportionately as the number of drugs taken increases. It may also be related to medications that are useful in the treatment of one disease may precipitate or worsen another condition.

This study showed that history of smoking, alcohol use, drug abuse and socio demographic characteristics such as sex, age, living condition, marital status, educational status and occupation of MDR-TB patients were not significantly associated with the development of adverse drug reactions. However, previous study has reported that age, sex, smoking and alcohol use had significant association with adverse drug reactions (4, 16-20). The possible explanation for this disparity might be the existence of variation with regard to genetic factors, culture, belief and living conditions. It might also be related to difference in the number of study participants used among the studies.

257 Strengths and Limitations of the study

Clinical record reviewed using pre-tested structured data collection format which minimizeinformation bias. Data quality was assured by trained nurse data collectors and close supervision.

The use of complete data from registers and patient cards, and for the reporting of adverse drug 260 reactions and associated factors is also one the strength of this study. Whereas the Reporting bias 261 might exist, as data were obtained retrospectively through medical card review, especially for 262 adverse events not defined by laboratory tests, such as gastrointestinal disorders, which might 263 overestimate or underestimate the magnitude of adverse events. Some important confounding 264 factors might not have been collected in this study. Electronic medical records are designed for 265 daily use in hospital clinical diagnosis and treatment, not for analysis of adverse reactions/events 266 267 of drugs used, so the records might lack some information needed to detect adverse events, and these were likely to result in bias of the study. 268

269 Conclusion and recommendation

During the study period, the prevalence of adverse drug reaction among MDR-TB patients wasfound to be higher. Majority of the study participants experienced more than one adverse drug

272 reactions. Nausea, vomiting followed by dyspepsia and abdominal pain and arthralgia were the273 commonly reported ADRs.

The study showed that comorbidity and treatment outcomes were the independent determinants adverse drug reaction among MDR-TB patients in the hospital. However, socio-demographic variables and behavioral factors were not significantly associated with the development of ADRs

Based on the finding of this study, the following important recommendations are forwarded management strategies should be strengthened to minimize ADR occurrence and for better treatment outcome. MDR-TB Patients having comorbid diseases should be closely monitored and gave special counseling to minimize the development of ADRs. Patients should be educated on the possible ADRs of MDR-TB drugs. Further investigation should be performed emphasizing the occurrence of adverse events in different phases of MDR-TB treatment, and corresponding relationships with comorbidities, sociodemographic and behavioral variables.

284 **Disclosure**

285 The authors reports no both financial and non -financial competing interest in these works

286 **Reference**

- 1.Federal minstry of Health(FMOH) Tuberculosis, Leprosy, and TB/HIV Prevention and Control
 Programme Manual, 4th ed., Addis Ababa, Ethiopia. 2008.
- 2.FMHACA. Guideline for Adverse Drug Events Monitoring (Pharmacovigilance), 3rd ed., Addis Ababa,
 Ethiopia. 2014.
- 291 3.World Health Organization(WHO). Global Tuberculosis Report, 20th ed., Geneva. 2015.

- 4.Haregewoin B. DS, Getnet Y, Tesfamariam, M. Prevalence and Risk Factors of Adverse Drug Reactions
- 293 Associated Multidrug Resistant Tuberculosis Treatments in Selected Treatment Centers in Addis Ababa
- Ethiopia.Journal of Tuberculosis Research, 2, 144-154. 2014;2:144-54.
- 5.Yohanna KA. PI, Sven GH. Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with
- 296 Multidrug-Resistant Tuberculosis in Nigeria. Journalpone 2015;10(3).
- 297 6.S. S. Shin ADP, I. Y. Gelmanova Adverse reactions among patients being treated for MDR-TB in
- Tomsk, Russia. . The International Journal of Tuberculosis and Lung Disease 2007;11(12):1314–20.
- 299 7.Nguyen BH. NV, Pham HK., Nguyen VH, Bui TTQ. Adverse events in the treatment of MDR-TB
- 300 patients within and outside the NTP in Pham Ngoc Thach hospital, Ho Chi Minh City, Vietnam. . BMC
- 301 Research Notes 2015;8:809.
- 302 8.Kishor BR. MS, Avinash RL., Sanjay LS., Gajanan AS., Vimlesh RP. . Adverse events among patients
- of multi drug resistant tuberculosis receiving second line anti TB treatment. International Journal of
 Scientific Reports. 2015;1(6):253-7
- 305 9.Petros I, Bhanumati, V., Homa, M., Helen, S.C., Joanna, L., Peter, S., Esdras, S., Samsuddin, K., Roma,
- 306 P., Zarir, U., Giovanni, B.M., Giovanni, S, Tony, R. Adverse Events among HIV/MDR-TB Co-Infected
- Patients Receiving Antiretroviral and Second Line Anti-TB Treatment in Mumbai, India. . PLos ONE
 2012;7: e40781.
- 309 10.Dela AI TN, Singh AP, Piparva KG. Adverse drug reactions and treatment outcome analysis of
- 310 DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study.
- Lung India: official organ of Indian Chest Society. 2017;34(6):522–6.
- 312 11.Dominica C, Cristian, D., Niculae, G., Radu, P. and Constantin, M. . Individualized Treatment
- Regimens with Second Line Anti-TB Drugs (SLD) Compared to First Line Anti-TB Drug (FLD) Only in
- New Pulmonary TB Patients, Culture Confirmed with Full Sensibility at Drug Sensibility Test (DST).
- Thematic Poster Session, 4406. 2011.
- 316 12.Mahajan S, Tandon, V.R, Kuma, S. Women and Risk for Developing ADR's. JK Science 2012;14(1).

- 317 13.JA M. Factors affecting the development of adverse drug reactions (Review article).Saudi
 318 Pharmaceutical Journal 2012;22:83-94.
- 319 14.WHO. A practical handbook on the pharmacovigilance of drugs used in the treatment of tuberculosis:
- Enhancing the safety of the TB patient. WHO document WHO/CDS/TB. 2012.
- 321 15.Sangita VP. NK, Alpesh B., Kalpita SS., Kedar GM, Lipy KS. Adverse Drug Reactions in Patients put
- 322 on Multi Drug Resistant Tuberculosis (MDR-TB) Treatment in Seven Districts of Central Gujarat. .
- 323 Journal of Young Pharmacists 2015;7(4).
- 324 16.Rohan H. ASK, G. N. Dakhale , Nilesh G. A Prospective, Observational Study of Adverse Reactions
- 325 to Drug Regimen for Multi-Drug Resistant Pulmonary Tuberculosis in Central India. Mediterranean
- Journal of Hematology and Infectious Diseases 2014;6(1).
- 327 17.A. S. Assessment of Knowledge Attitude and Practices of Tuberculosis Patients Towards Tuberculosis
- and its Treatment in Addis Ababa City Government, Ethiopia, MPH thesis, Addis Ababa University,
 Addis Ababa. 2011.
- 18.J. J.Furin CDM, S. S. Shin.The International Journal of Tuberculosis and Lung Disease.
 2001;5(7):648–55.
- 332 19.M. G. Prevalence of MDR-TB and Treatment Outcome Among Tuberculosis Patients Attending at St.
- Peter TB Specialized Hospital Addis Ababa, Ethiopia, MSc thesis, Addis Ababa University, AddisAbaba. 2014.
- 20.J. S. Akshata AC, R. Swapn, Shashidhar B., M. Somashekar. Adverse Drug Reactions in Management
 of Multi Drug Resistant Tuberculosis, in Tertiary Chest Institute. Journal of Tuberculosis Research
 2015;3:27-33.
- 338

339 List of tables

340 Table 1: Socio-demographic characteristics of MDR-TB patients attending St. Peter

341 hospital, Addis Ababa, 2020.

Frequency	Percent	
127	44.4	
159	55.6	
166	58.3	
68	23.9	
26	8.8	
11	3.9	
15	5.3	
136	47.6	
138	48.3	
4	1.4	
8	2.8	
	127 159 166 68 26 11 15 15 136 138 4	

181	63.3
45	15.7
24	8.4
36	12.4
27	9.4
30	10.5
99	34.6
86	30.1
18	6.3
26	9.1
30	10.5
19	6.6
17	5.9
75	26.2
18	6.3
	45 24 36 27 30 99 86 18 26 30 19 17 75

Student		75	26.2
Others***	6	52	18.2

342

Table 2: Clinical characteristics of MDR-TB patients attending St. Peter hospital, Addis Ababa,

344 2020.

Characteristics	Frequency	Percent
Site TB		
РТВ	270	94.4
ЕРТВ	16	5.6
Registration group		
New	42	14.7
Relapse	43	15.0
After lost to follow up	6	2.1
After failure of first treatment	121	42.3
After failure of re-treatment	74	25.9
Previous second line drug use		
Yes	11	3.85
No	275	96.15
Co-morbidities		
Yes	17	5.90
No	269	94.10

Base-line BMI category		
<18.5Kg/m2	186	65.03
18.5-24.9Kg/m2	97	33.92
>=24.9 Kg/m2	3	1.05

Table 3: Adverse drug reactions which occurred among the patients attending St. Peter hospital,

346 Addis Ababa, 2020.

ADR	Frequency	Percent
Rash	12	7.1
Nausea and vomiting	97	57.4
Dyspepsia and abdominal pain	74	44
Diarrhea	8	4.7
Hepatitis	3	1.8
Arthralgia	73	43.5
Electrolyte abnormalities	5	3
Nephrotoxicity	9	5.4
Ototoxicity	8	4.8
Peripheral neuropathy	13	7.7
Depression	12	7.1
Headache	38	22.5
Psychosis	12	7.1
Seizures	2	1.2

Hypothyroidism	2	1.2
Anxiety	11	6.5
Insomnia	36	21.3
Visual disturbances	14	8.3
Musculoskeletal pain	10	6
Vestibular toxicity	10	6
Anorexia	32	18.9
Pain at the injection site	5	3
Others***	27	16

347 ***Fever, sweating, body weakness, anemia, weight loss, palpitation, fungal infection, vaginal
348 discharge.

Table 4: Treatment outcomes and the most common anti-TB regimens used among patients in

350 St. Peter hospital, Addis Ababa, 2020.

Treatment outcomes	Frequency	Percent	
Cured	78	27.3	
Completed	153	53.5	
Lost to follow up	23	8.0	
Died	23	8.0	
Failure	9	2.1	
Regimen			
Cm, Lfx, Pto/ Eto, Cs, Z	251	87.8	
Cm, Lfx, Pto/ Eto, Cs, PAS, Z	12	4.2	

Cm, Lfx, E, Pto/ Eto, Cs, Z	6	2.1

351


352 Table 5: Multivariate analysis of factors for Adverse Drug Reaction among the patients attending

353 St. Peter hospital, Addis Ababa, 2020.


Variables	COR (95%CI)	P value	AOR (95%CI)	P value
Age group (years)				
18-27	0.486(0.165 - 1.429)	0.190	1.098(0.306 - 3.938)	0.886
28-37	0.496(0.159 - 1.549)	0.227	0.960(0.251 - 3.671)	0.952
38-47	0.200(0.050 - 0.794)	0.022	3.632(0.778 - 16.949)	0.101
48-57	0.250(0.047 - 1.344)	0.106	3.311(0.480 - 22.849)	0.224
>58	1		1	
History of				
Cigarette Smoking				
Yes	4.792(1.061 - 21.649)	0.042	2.889(0.510 - 16.367)	.231
No	1		1	
Co-morbidities				
Yes	5.601(1.256 - 24.976)	0.024	5.809(1.106 - 30.504)	0.038
No	1		1	
Treatment				
outcomes				

Cured	0.104(0.024 - 0.462)	0.003	10.012(2.131 - 47.036)	0.004
Complete	0.730(0.189 - 2.823)	0.648	1.367(0.334 - 5.601)	0.664
LTFU	1.829(0.374 - 8.937)	0.783	0.657(0.126 - 3.426)	0.618
Died	1.829(0.374 - 8.937)	0.456	0.366(0.064 - 2.083)	0.257
Failure	1		1	

354 List of figures



- Figure 1: Schematic representation of selection of patient profile cards among the patients
- attending St. Peter hospital, Addis Ababa, 2009 2016.



360 − 2016.